Literature DB >> 35372991

Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases.

Tiffany N Caza1, Clarissa A Cassol1, Nidia Messias1, Andrew Hannoudi2, Randy S Haun1, Patrick D Walker1, Rebecca M May1, Regan M Seipp3, Elizabeth J Betchick4, Hassan Amin5, Mandolin S Ziadie6, Michael Haderlie7, Joy Eduwu-Okwuwa8, Irina Vancea9, Melvin Seek10, Essam B Elashi11, Ganesh Shenoy12, Sayeed Khalillullah13, Jesse A Flaxenburg14, John Brandt15, Matthew J Diamond16, Adam Frome17, Eugene H Kim18, Gregory Schlessinger19, Erlandas Ulozas20, Janice L Weatherspoon21, Ethan Thomas Hoerschgen22, Steven L Fabian23, Sung Yong Bae24, Bilal Iqbal25, Kanwalijit K Chouhan26, Zeina Karam27, James T Henry28, Christopher P Larsen1.   

Abstract

Background: Immune responses to vaccination are a known trigger for a new onset of glomerular disease or disease flare in susceptible individuals. Mass immunization against SARS-CoV-2 in the COVID-19 pandemic provides a unique opportunity to study vaccination-associated autoimmune kidney diseases. In the recent literature, there are several patient reports demonstrating a temporal association of SARS-CoV-2 immunization and kidney diseases.
Methods: Here, we present a series of 29 cases of biopsy-proven glomerular disease in patients recently vaccinated against SARS-CoV-2 and identified patients who developed a new onset of IgA nephropathy, minimal change disease, membranous nephropathy, ANCA-associated GN, collapsing glomerulopathy, or diffuse lupus nephritis diagnosed on kidney biopsies postimmunization, as well as recurrent ANCA-associated GN. This included 28 cases of de novo GN within native kidney biopsies and one disease flare in an allograft.
Results: The patients with collapsing glomerulopathy were of Black descent and had two APOL1 genomic risk alleles. A brief literature review of patient reports and small series is also provided to include all reported cases to date (n=52). The incidence of induction of glomerular disease in response to SARS-CoV-2 immunization is unknown; however, there was no overall increase in incidence of glomerular disease when compared with the 2 years prior to the COVID-19 pandemic diagnosed on kidney biopsies in our practice. Conclusions: Glomerular disease to vaccination is rare, although it should be monitored as a potential adverse event.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  ANCA; APOL1; COVID-19; IgA nephropathy; SARS-CoV-2 vaccine; collapsing glomerulopathy; crescentic glomerulonephritis; glomerular and tubulointerstitial diseases; lupus nephritis; membranous nephropathy; minimal change disease

Mesh:

Substances:

Year:  2021        PMID: 35372991      PMCID: PMC8785835          DOI: 10.34067/KID.0005372021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  50 in total

1.  Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Hirotaka Komaba; Takehiko Wada; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2021-05-20       Impact factor: 8.860

2.  Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.

Authors:  Peggy Perrin; Xavier Bassand; Ilies Benotmane; Nicolas Bouvier
Journal:  Kidney Int       Date:  2021-06-01       Impact factor: 10.612

3.  Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Larissa Lebedev; Marina Sapojnikov; Alexander Wechsler; Ronen Varadi-Levi; Doron Zamir; Ana Tobar; Nomy Levin-Iaina; Shlomo Fytlovich; Yoram Yagil
Journal:  Am J Kidney Dis       Date:  2021-04-08       Impact factor: 8.860

4.  Reactivation of IgA vasculitis after COVID-19 vaccination.

Authors:  Michel Obeid; Craig Fenwick; Giuseppe Pantaleo
Journal:  Lancet Rheumatol       Date:  2021-07-06

5.  Impact of COVID-19 pandemic on SLE: beyond the risk of infection.

Authors:  Alice Horisberger; Laura Moi; Camillo Ribi; Denis Comte
Journal:  Lupus Sci Med       Date:  2020-05

6.  A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination.

Authors:  Shab E Gul Rahim; Jonathan T Lin; John C Wang
Journal:  Kidney Int       Date:  2021-04-28       Impact factor: 10.612

7.  Relapse of Class V Lupus Nephritis after Vaccination with COVID-19 mRNA Vaccine.

Authors:  Katharina Tuschen; Jan Hinrich Bräsen; Jessica Schmitz; Martin Vischedyk; Alexander Weidemann
Journal:  Kidney Int       Date:  2021-08-02       Impact factor: 10.612

8.  A Case of Membranous Nephropathy Following Pfizer-BioNTech mRNA vaccine against Coronavirus 2019.

Authors:  Yi Da; Giap Hean Goh; Priyanka Khatri
Journal:  Kidney Int       Date:  2021-07-29       Impact factor: 10.612

9.  Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.

Authors:  Amy Holzworth; Patrick Couchot; Wanda Cruz-Knight; Michael Brucculeri
Journal:  Kidney Int       Date:  2021-05-26       Impact factor: 10.612

View more
  10 in total

1.  Collapsing Glomerulonephritis in a Kidney Transplant Recipient after mRNA SARS-CoV-2 Vaccination.

Authors:  Francisco Gómez Preciado; Rosa Alejandra De Carvalho Ovalles; Sergi Codina; Laura Donadeu; Alexandre Favà; Laura Martinez Valenzuela; Diego Sandoval; Bárbara Fernández-Cidón; Oriol Bestard; Pedro Alia-Ramos; Montserrat Gomà; Edoardo Melilli; Josep M Cruzado
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

2.  Newly-diagnosed immunoglobulin A nephropathy with increased plasma galactose-deficient-IgA1 antibody associated with mRNA COVID-19 vaccination: a case report.

Authors:  Yun-Sung Chen; Cheng-Wen Yang; Chien-Chen Tsai; Min-De Ang; San-Fang Chou; Wen-Chih Chiang; Yen-Ling Chiu
Journal:  J Int Med Res       Date:  2022-10       Impact factor: 1.573

3.  Probable Vogt-Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review.

Authors:  Xinyi Ding; Qing Chang
Journal:  Vaccines (Basel)       Date:  2022-05-16

Review 4.  Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review.

Authors:  Eva Baier; Ulrike Olgemöller; Lorenz Biggemann; Cordula Buck; Björn Tampe
Journal:  Vaccines (Basel)       Date:  2022-04-21

5.  Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases.

Authors:  Aurélie Hummel; Julie Oniszczuk; Delphine Kervella; Marina Charbit; Dominique Guerrot; Angelo Testa; Carole Philipponnet; Cécile Chauvet; Thomas Guincestre; Karine Brochard; Ariane Benezech; Lucile Figueres; Xavier Belenfant; Andrea Guarnieri; Nathalie Demoulin; Elisa Benetti; Marius Miglinas; Kathleen Dessaix; Johann Morelle; Andrea Angeletti; Anne-Laure Sellier-Leclerc; Bruno Ranchin; Guillaume Goussard; Laurent Hudier; Justine Bacchetta; Aude Servais; Vincent Audard
Journal:  Clin Kidney J       Date:  2022-05-06

Review 6.  ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review.

Authors:  Arun Prabhahar; G S R S N K Naidu; Aravind Sekar; Prabhat Chauhan; Aman Sharma; Alok Sharma; Asheesh Kumar; Ritambhra Nada; Manish Rathi; Harbir Singh Kohli; Raja Ramachandran
Journal:  Rheumatol Int       Date:  2022-02-05       Impact factor: 3.580

7.  Acute interstitial nephritis after vaccination with BNT162b2.

Authors:  Sonja Rieckmann; Felix S Seibert; Maximilian Hogeweg; Sebastian Bertram; Adrian A N Doevelaar; Kerstin Amann; Nina Babel; Timm H Westhoff
Journal:  J Nephrol       Date:  2022-03-07       Impact factor: 4.393

8.  Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination.

Authors:  Yuri Uchiyama; Hirotaka Fukasawa; Yuri Ishino; Daisuke Nakagami; Mai Kaneko; Hideo Yasuda; Ryuichi Furuya
Journal:  BMC Nephrol       Date:  2022-06-21       Impact factor: 2.585

9.  Post Covishield (ChAdOx1 nCoV-19) Vaccination: New Onset Focal Segmental Glomerulosclerosis Resistant to Steroid and Calcineurin Inhibitor.

Authors:  Vijoy Kumar Jha; Ramanjit Singh Akal; Alok Sharma; Debasish Mahapatra
Journal:  Indian J Nephrol       Date:  2022-07-16

10.  Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2.

Authors:  Juan Irure-Ventura; Lara Belmar-Vega; Gema Fernández-Fresnedo; Elena González-López; Carolina Castro-Hernández; Emilio Rodrigo-Calabia; Milagros Heras-Vicario; Juan Carlos Ruiz San Millán; Marcos López-Hoyos
Journal:  iScience       Date:  2022-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.